Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 7/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13689085 | 0.85 | CYP17A1 (0.39) | CYP17A1CYP19A1ALDH1A1MEN1KMT2A | |
| SCHEMBL3323577 | 0.84 | RAB9A (0.43) | ALDH1A1MEN1KMT2AHSD11B1KDM4E | |
| SCHEMBL3322670 | 0.83 | P2RX7 (0.43) | ALDH1A1HSD11B1KDM4ESMN1; SMN2 | |
| SCHEMBL1769926 | 0.81 | CYP17A1 (0.52) | CYP17A1CYP19A1ALDH1A1MEN1KMT2A | |
| SCHEMBL1769896 | 0.78 | GRM5 (0.47) | ALDH1A1MEN1KMT2AHSD11B1KDM4E | |
| SCHEMBL3323123 | 0.78 | ALDH1A1 (0.53) | ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3322001 | 0.76 | HSD11B1 (0.48) | ALDH1A1KMT2AHSD11B1KDM4E | |
| SCHEMBL1770354 | 0.76 | MEN1 (0.42) | ALDH1A1MEN1KMT2AHSD11B1KDM4E | |
| SCHEMBL10349958 | 0.72 | ALDH1A1 (0.42) | ALDH1A1MEN1KMT2AHSD11B1KDM4E | |
| SCHEMBL13688859 | 0.72 | CYP17A1 (0.31) | CYP17A1CYP19A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | HSD11B1, HSD11B2, HSD3B1 | CYP17A1 23/4885CYP19A1 112/4885ALDH1A1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.